Bevacizumab Plus Capecitabine Chemotherapy for Metastatic Colorectal Cancer in Hemodialysis Patients:

Four Case Reports

Abstract

There is little evidence of chemotherapy for cancer patients undergoing hemodialysis. We report four hemodialysis patients with metastatic colorectal cancer who received bevacizumab plus capecitabine chemotherapy. Patients were administered bevacizumab 7.5 mg/kg every 3 weeks and capecitabine in a one-step dose reduction of 1,000 mg/m² twice a day for 2 weeks of every 3 weeks from Monday to Friday. If adverse effects were well tolerated, capecitabine was increased up to 1,000 mg/m². After chemotherapy started, chemotherapy decreased CEA and CA19-9 levels in all patients and chemotherapy was effective in 3 of 4 patients who underwent computed tomography examination. Chemotherapy was discontinued due to thrombocytopenia and infection but its adverse effects were reversible. These cases suggest bevacizumab plus capecitabine chemotherapy can be administered for hemodialysis patients.